As filed with the Securities and Exchange Commission on January 20, 2015
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
KERYX BIOPHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware |
|
13-4087132 |
(State or Other Jurisdiction of
Incorporation or Organization) |
|
(I.R.S. Employer
Identification No.) |
750 Lexington Avenue
New York, New York 10022
(212) 531-5965
(Address,
Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
James F.
Oliviero
Chief Financial Officer
Keryx Biopharmaceuticals, Inc.
750 Lexington Avenue
New
York, New York 10022
(212) 531-5965
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)
The Commission is requested to send copies of all communications to:
Mark F. McElreath, Esq.
Matthew W. Mamak, Esq.
Alston & Bird LLP
90 Park Avenue
New York,
New York 10016
Telephone: (212) 210-9595
Approximate
date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the
following box. ¨
If any of the securities being registered on this Form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. x
If this Form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. x
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
x |
|
Accelerated filer |
|
¨ |
|
|
|
|
Non-accelerated filer |
|
¨ (Do not check if smaller reporting company) |
|
Smaller reporting company |
|
¨ |
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
Title of Each Class Of
Securities To Be Registered(1) |
|
Proposed
Maximum Aggregate
Offering Price |
|
Amount of
Registration Fee(2) |
Common Stock, $0.001 par value per share |
|
|
|
|
Total |
|
$115,000,000 |
|
$ |
|
|
(1) |
Such indeterminate number of shares of Common Stock of Keryx Biopharmaceuticals, Inc. as may from time to time be issued at indeterminate prices. Pursuant to Rule 416 under the Securities Act of 1933, as amended, such
number of shares of Common Stock registered hereby shall include an indeterminate number of shares of Common Stock that may be issued in connection with a stock split, stock dividend, recapitalization or similar event. |
(2) |
In accordance with Rules 456(b) and 457(r), the registrants are deferring payment of all of the registration fee and will pay the registration fee subsequently in advance or on a pay-as-you-go basis. |
The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall
become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
PROSPECTUS
$115,000,000
Keryx
Biopharmaceuticals, Inc.
Common Stock
We may offer
and sell an indeterminate number of shares of our common stock from time to time under this prospectus. You should read this prospectus and any prospectus supplement carefully before you invest.
We may offer our common stock in one or more offerings in amounts, at prices, and on terms determined at the time of the offering. We may sell
our common stock through agents we select or through underwriters and dealers we select. If we use agents, underwriters or dealers, we will name them and describe their compensation in a prospectus supplement.
This prospectus provides a general description of the securities we may offer. Each time we sell securities, we will provide specific terms of
the securities offered in a supplement to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus and the applicable prospectus supplement carefully before
you invest in any securities. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement.
Our common stock is traded on the Nasdaq Capital Market under the symbol KERX. On January 16, 2015, the per share closing price of
our common stock as reported on the Nasdaq Capital Market was $14.22 per share.
Investing in
our securities involves certain risks. See Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2013, as well as our Quarterly Reports on Form 10-Q for the periods ended March 31,
2014, June 30, 2014 and September 30, 2014, which have been filed with the SEC and are incorporated by reference into this prospectus. You should read the entire prospectus carefully before you make your investment decision.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of
this prospectus is January 20, 2015
Table of Contents
- i -
KERYX BIOPHARMACEUTICALS, INC.
We are a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease. We are
developing AURYXIA (ferric citrate), an oral, ferric iron-based compound. In September 2014, we announced that the U.S. Food and Drug Administration, or FDA, approved Auryxia (formerly known as Zerenex) for the control of serum phosphorus
levels in patients with chronic kidney disease, or CKD, on dialysis. The U.S. approval of Auryxia was based on data from our Phase 3 registration program. In the Phase 3 clinical trials, Auryxia effectively reduced serum phosphorus levels to well
within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative, or KDOQI, guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased
ferritin, iron and transferrin saturation, or TSAT, whereas these parameters remained relatively constant in patients treated with active control (Renvela®and/or Phoslo®). The most common adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. In December 2014, we announced that we
had begun shipping Auryxia tablets to wholesalers in the U.S.
End-stage renal disease, or ESRD represents the most severe stage of CKD,
as many metabolic factors, such as iron and phosphorus, are out of balance. The majority of ESRD patients require chronic treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. In addition, iron can be
severely depleted in dialysis patients and they therefore are often treated with intravenous iron and other medications. Approximately 450,000 ESRD patients required dialysis in the U.S. in 2012.
We have created the Keryx Patient Plus program to assist with patient accessibility to Auryxia. Beginning at our reimbursement
hub, personalized service is provided through dedicated regional case managers to provide the renal care team with comprehensive insurance and reimbursement support for their patients. Keryx Patient Plus offers benefit verification, co-pay
assistance for eligible commercial patients, free-drug program for those who qualify, and a short-term prescription bridge program that may assist those already on Auryxia who are in danger of suffering a break in coverage.
In addition, in March 2014, we submitted a Marketing Authorization Application, or MAA, with the European Medicines Agency, or EMA, seeking
the approval of Auryxia as a treatment for hyperphosphatemia in patients with CKD, including dialysis and non-dialysis dependent CKD, or NDD-CKD. Also in March 2014, the EMA validated our MAA, confirming that the submission is sufficiently complete
to begin the formal review process.
We have also completed a U.S.-based Phase 2 study of Auryxia for the management of elevated serum
phosphorus levels and iron deficiency in subjects with Stage 3 to 5 NDD-CKD, and in September 2014, we initiated a pivotal Phase 3 study of Auryxia for the treatment of iron deficiency anemia in patients with Stage 3 to 5 NDD-CKD.
Currently, our only drug product is Auryxia. We may engage in business development activities that include seeking strategic relationships for
Auryxia, as well as evaluating other compounds and companies for in-licensing or acquisition. We have also generated, and expect to continue to generate, revenue from the sublicensing of rights to Auryxia in Japan to our Japanese partner, JT and
Torii.
Our principal executive offices are located at 750 Lexington Avenue, New York, New York 10022, and our telephone number is
(212) 531-5965. We maintain a website on the Internet at www.keryx.com and our e-mail address is info@keryx.com. Our Internet website, and the information contained on it, are not to be considered part of this prospectus.
1
THE OFFERING
|
|
|
Use of Proceeds |
|
We intend to use the net proceeds of any offering as set forth in the applicable prospectus supplement. |
|
|
Nasdaq Symbol |
|
KERX |
WHERE YOU CAN FIND MORE INFORMATION
We file reports with the SEC on an annual basis using Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. You may read
and copy any such reports and amendments thereto at the SECs Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 on official business days during the hours of 10:00 a.m. to 3:00 p.m. Please call the SEC at 1-800-SEC-0330 for
information on the Public Reference Room. Additionally, the SEC maintains a website that contains annual, quarterly, and current reports, proxy statements, and other information that issuers (including us) file electronically with the SEC. The
SECs website address is http://www.sec.gov. You can also obtain copies of materials we file with the SEC from our Internet website found at www.keryx.com. Our stock is quoted on the Nasdaq Capital Market under the symbol KERX.
IMPORTANT INFORMATION ABOUT THIS PROSPECTUS
This prospectus is part of a shelf registration statement that we filed with the SEC. By using a shelf registration statement, we
may sell our securities, as described in this prospectus, from time to time in one or more offerings. We may use the shelf registration statement to offer and sell securities described in this prospectus. Each time we sell securities, we will
provide a prospectus supplement to this prospectus that contains specific information about the terms of such offering. The supplement may also add, update or change information contained in this prospectus. Before purchasing any securities, you
should carefully read both this prospectus and any supplement, together with the additional information incorporated into this prospectus or described under the heading Where You Can Find More Information.
You should rely only on the information contained or incorporated by reference in this prospectus and any prospectus supplement. We have not
authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We will not make an offer to sell securities in any jurisdiction where the offer or
sale is not permitted. You should assume that the information appearing in this prospectus, as well as information we previously filed with the SEC and have incorporated by reference, is accurate as of the date on the front cover of this prospectus
only, or when such document was filed with the SEC. Our business, financial condition, results of operations and prospects may have changed since the relevant date.
We will not use this prospectus to offer and sell securities unless it is accompanied by a prospectus supplement that more fully describes the
terms of the offering.
2
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to incorporate by reference into this prospectus the information we file with the SEC. This means that we can
disclose important information to you by referring you to those documents without restating that information in this document. The information incorporated by reference into this prospectus is considered to be part of this prospectus, and
information we file with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, after the date of this prospectus and prior to the termination of this offering, will
automatically update and supersede the information contained in this prospectus and documents listed below. We incorporate by reference into this prospectus the documents listed below, except to the extent information in those documents differs from
information contained in this prospectus, and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including exhibits:
|
(a) |
Our Annual Report on Form 10-K for the year ended December 31, 2013; |
|
(b) |
Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014; |
|
(c) |
Our Current Reports on Form 8-K filed with the SEC on January 17, 2014, January 28, 2014, February 10, 2014, March 12, 2014, May 22, 2014, June 24,
2014, September 5, 2014, November 17, 2014, November 18, 2014, December 11, 2014 and January 12, 2015; and |
|
(d) |
Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on October 10, 2014. |
We will provide to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, a copy of any or all of the
information that we have incorporated by reference into this prospectus. We will provide this information upon written or oral request at no cost to the requester. You may request this information by contacting our corporate headquarters at the
following address: 750 Lexington Avenue, New York, New York 10022, Attn: Chief Financial Officer, or by calling (212) 531-5965.
3
DESCRIPTION OF COMMON STOCK
The following summary of the terms of our common stock may not be complete and is subject to, and qualified in its entirety by reference to,
the terms and provisions of our amended and restated certificate of incorporation and our amended and restated bylaws. You should refer to, and read this summary together with, our amended and restated certificate of incorporation and amended and
restated bylaws to review all of the terms of our common stock that may be important to you.
Common Stock
Under our certificate of incorporation, we are authorized to issue a total of 130,000,000 shares of common stock, par value $0.001 per share.
As of January 19, 2015, we had issued and outstanding 93,072,366 shares of our common stock. There are approximately 52 holders of record. All outstanding shares of our common stock are fully paid and nonassessable. Our common stock is listed on the
Nasdaq Capital Market under the symbol KERX.
Dividends
Subject to the dividend rights of the holders of any outstanding series of preferred stock, holders of our common stock are entitled to receive
ratably such dividends and other distributions of cash or any other right or property as may be declared by our board of directors out of our assets or funds legally available for such dividends or distributions.
Voting Rights
The holders of our common
stock are entitled to one vote for each share of common stock owned by that stockholder on every matter properly submitted to the stockholders for their vote. Stockholders are not entitled to vote cumulatively for the election of directors.
Liquidation and Dissolution
In the event
of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of common stock would be entitled to share ratably in our assets that are legally available for distribution to stockholders after payment of liabilities.
If we have any preferred stock outstanding at such time, holders of the preferred stock may be entitled to distributions and/or liquidation preferences. In either such case, we must pay the applicable distribution to the holders of our preferred
stock (if any) before we may pay distributions to the holders of common stock.
Other
Holders of our common stock have no conversion, redemption, preemptive, subscription or similar rights.
Transfer Agent
American Stock Transfer
and Trust Company serves as the transfer agent and registrar for all of our common stock.
4
PLAN OF DISTRIBUTION
We may sell the securities covered in this prospectus in any of three ways (or in any combination):
|
|
|
through underwriters or dealers; |
|
|
|
directly to a limited number of purchasers or to a single purchaser; or |
Each time that we use this prospectus to sell securities, we will also
provide a prospectus supplement that contains the specific terms of the offering. The prospectus supplement will set forth the terms of the offering of the securities, including:
|
|
|
the name or names of any underwriters, dealers or agents and the amounts of any securities underwritten or purchased by each of them; and |
|
|
|
the public offering price of the common stock and the proceeds to us and any discounts, commissions or concessions allowed or reallowed or paid to dealers. |
Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.
If underwriters are used in the sale of any securities, the securities will be acquired by the underwriters for their own account and may be
resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The securities may be either offered to the public through underwriting
syndicates represented by managing underwriters, or directly by underwriters. Generally, the underwriters obligations to purchase the securities will be subject to certain conditions precedent. The underwriters will be obligated to purchase
all of the securities if they purchase any of securities.
We may sell the securities through agents from time to time. The prospectus
supplement will name any agent involved in the offer or sale of the securities and any commissions we pay to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment.
We may authorize underwriters, dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public
offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in the prospectus
supplement, and the prospectus supplement will set forth any commissions we pay for solicitation of these contracts.
Agents and
underwriters may be entitled to indemnification by us against certain civil liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribution with respect to payments which the agents or underwriters may be required
to make in respect thereof. Agents and underwriters may be customers of, engage in transactions with, or perform services for us in the ordinary course of business.
We may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately
negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale
transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of securities, and may use securities received from us in settlement of those
derivatives to close out any related open borrowings of securities. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a post-effective amendment).
5
In compliance with the guidelines of the Financial Services Regulatory Authority, Inc., or FINRA,
the maximum compensation to be received by a FINRA member or independent broker-dealer may not exceed 8% of the offering proceeds. It is anticipated that the maximum compensation to be received in any particular offering of securities will be less
than this amount.
LEGAL MATTERS
The legality and validity of the securities offered from time to time under this prospectus will be passed upon by Alston & Bird LLP,
New York, New York.
EXPERTS
The consolidated financial statements of Keryx Biopharmaceuticals, Inc. and subsidiaries as of December 31, 2013 and 2012, and for each
of the years in the three year period ended December 31, 2013, have been incorporated by reference herein in reliance upon the report of UHY LLP, independent registered public accounting firm, and upon the authority of said firm as experts in
accounting and auditing.
6
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
ITEM 14. |
OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION. |
The table below itemizes the expenses
payable by the Registrant in connection with the registration and issuance of the securities being registered hereunder, other than underwriting discounts and commissions. All amounts except the Securities and Exchange Commission registration fee
are estimated.
|
|
|
|
|
Securities and Exchange Commission Registration Fee |
|
$ |
|
(1) |
|
|
Legal Fees and Expenses |
|
$ |
|
(2) |
|
|
Accountants Fees and Expenses |
|
$ |
|
(2) |
|
|
Printing and Duplicating Expenses |
|
$ |
|
(2) |
|
|
Transfer Agent and Registrars Fees and Expenses |
|
$ |
|
(2) |
|
|
Miscellaneous Expenses |
|
$ |
|
(2) |
|
|
Total |
|
$ |
|
(2) |
(1) |
To be determined. The registrant is deferring payment of the registration fee in reliance on Rule 456(b) and Rule 457(r) under the Securities Act. |
(2) |
These fees are calculated based on the numbers of issuances and amount of securities offered and, accordingly, cannot be estimated at this time. |
ITEM 15. |
INDEMNIFICATION OF DIRECTORS AND OFFICERS. |
Under the General Corporation Law of the
State of Delaware, or DGCL, a corporation may include provisions in its certificate of incorporation that will relieve its directors of monetary liability for breaches of their fiduciary duty to the corporation, except under certain circumstances,
including a breach of the directors duty of loyalty, acts or omissions of the director not in good faith or which involve intentional misconduct or a knowing violation of law, the approval of an improper payment of a dividend or an improper
purchase by the corporation of stock or any transaction from which the director derived an improper personal benefit. The Registrants Amended and Restated Certificate of Incorporation eliminates the personal liability of directors to the
Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director with certain limited exceptions set forth in the DGCL.
Section 145 of the DGCL grants to corporations the power to indemnify each officer and director against liabilities and expenses incurred
by reason of the fact that he or she is or was an officer or director of the corporation if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with
respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The Registrants Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide for indemnification of
each officer and director of the Registrant to the fullest extent permitted by the DGCL. Section 145 of the DGCL also empowers corporations to purchase and maintain insurance on behalf of any person who is or was an officer or director of the
corporation against liability asserted against or incurred by him in any such capacity, whether or not the corporation would have the power to indemnify such officer or director against such liability under the provisions of Section 145 of the
DGCL.
II-1
|
|
|
Exhibit Number |
|
Description |
|
|
1.1 |
|
Underwriting Agreement* |
|
|
4.1 |
|
Specimen Common Stock Certificate, filed as Exhibit 4.1 to the Registrants First Amendment to the Registration Statement on Form S-1 filed on June 30, 2000 (File No. 333-37402), and incorporated herein by reference. |
|
|
5.1 |
|
Opinion of Alston & Bird LLP |
|
|
23.1 |
|
Consent of UHY LLP |
|
|
23.3 |
|
Consent of Alston & Bird LLP (included in Exhibit 5.1) |
|
|
24.1 |
|
Power of Attorney (included on the signature page to this Registration Statement) |
* |
To be filed by amendment or as an exhibit to a document to be incorporated by reference herein in connection with an offering of our securities. |
The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
|
(i) |
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; |
|
(ii) |
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which
was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)) if, in the aggregate, the changes in volume and price
represent no more than 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective registration statement; and |
|
(iii) |
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
|
|
(2) |
That, for the purpose of determining any liability under the Securities Act of 1933, each such post- effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be initial bona fide offering thereof. |
|
(3) |
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
|
(5) |
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: |
|
(A) |
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the Registration Statement as of the date the filed prospectus was deemed part of and included in the Registration
Statement; and |
II-2
|
(B) |
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a Registration Statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or
(x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the Registration Statement as of the earlier of the date such form of prospectus is
first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the Registration Statement relating to the securities in the Registration Statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. Provided, however, that no statement made in a Registration Statement or prospectus that is part of the Registration Statement or made in a document incorporated or deemed incorporated by reference into the
Registration Statement or prospectus that is part of the Registration Statement will, as to the purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the Registration Statement or
prospectus that was part of the Registration Statement or made in any such document immediately prior to such effective date. |
|
(6) |
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: |
The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this Registration
Statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:
|
(i) |
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
|
(ii) |
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
|
(iii) |
The portion of any other free writing prospectuses relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
|
|
(iv) |
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
B. |
Filings Incorporating Subsequent Exchange Act Documents By Reference |
The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrants annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of
1934 (and, where applicable, each filing of an employee benefit plans annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
E. |
Incorporated annual and quarterly reports |
The undersigned registrant hereby
undertakes to deliver or cause to be delivered with the prospectus, to each person to whom the prospectus is sent or given, the latest annual report to security holders that is incorporated by reference in the prospectus and furnished pursuant to
and meeting the requirements of
II-3
Rule 14a-3 or Rule 14c-3 under the Securities Exchange Act of 1934; and, where interim financial information required to be presented by Article 3 of Regulation S-X are not set forth in the
prospectus, to deliver, or cause to be delivered to each person to whom the prospectus is sent or given, the latest quarterly report that is specifically incorporated by reference in the prospectus to provide such interim financial information.
H. |
Request for Acceleration of Effective Date or Filing of Registration Statement Becoming Effective Upon Filing |
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of
such issue.
I. |
The undersigned registrant hereby undertakes that: |
|
(1) |
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a
form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. |
|
(2) |
For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of New York, State of New York, on January 20, 2015.
|
|
|
KERYX BIOPHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Ron
Bentsur |
|
|
Ron Bentsur
Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Ron Bentsur, James F.
Oliviero and Brian Adams, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and his name, place and stead, in any and all capacities, to sign any or all amendments (including pre-effective
and post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, including any Registration Statement filed pursuant to Rule 462(b) under the Securities Act
of 1933, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he
might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of his substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons
in the capacities indicated as of January 20, 2015.
|
|
|
|
|
Signatures |
|
|
|
Title |
|
|
|
/s/ Ron
Bentsur |
|
|
|
Chief Executive Officer and Director |
Ron Bentsur |
|
|
|
|
|
|
|
/s/ James F.
Oliviero |
|
|
|
Chief Financial Officer and Treasurer |
James F. Oliviero |
|
|
|
|
|
|
|
/s/ Michael P.
Tarnok |
|
|
|
Chairman of the Board of Directors |
Michael P. Tarnok |
|
|
|
|
|
|
|
/s/ Kevin J.
Cameron |
|
|
|
Director |
Kevin J. Cameron |
|
|
|
|
|
|
|
/s/ Joseph Feczko,
M.D. |
|
|
|
Director |
Joseph Feczko, M.D. |
|
|
|
|
|
|
|
/s/ Wyche Fowler,
Jr. |
|
|
|
Director |
Wyche Fowler, Jr. |
|
|
|
|
|
|
|
/s/ Jack
Kaye |
|
|
|
Director |
Jack Kaye |
|
|
|
|
|
|
|
/s/ Daniel
Regan |
|
|
|
Director |
Daniel Regan |
|
|
|
|
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
5.1 |
|
Opinion of Alston & Bird LLP |
|
|
23.1 |
|
Consent of UHY LLP |
|
|
23.3 |
|
Consent of Alston & Bird LLP (included in Exhibit 5.1) |
|
|
24.1 |
|
Power of Attorney (included on the signature page to this Registration Statement) |
Exhibit 5.1
90 Park Avenue
New York, NY 10016
212-210-9400
Fax: 212-210-9444
www.alston.com
|
|
|
|
|
Mark F. McElreath |
|
Direct Dial: 212-210-9595 |
|
Email: mark.mcelreath@alston.com |
January 20, 2015
Keryx Biopharmaceuticals, Inc.
750 Lexington Avenue
New York, NY 10022
|
Re: |
Registration Statement on Form S-3 |
Gentlemen:
We have acted as counsel to Keryx Biopharmaceuticals, Inc., a Delaware corporation (the Company), in connection with the
registration statement (the Registration Statement) on Form S-3 filed today by the Company with the Securities and Exchange Commission (the Commission) under the Securities Act of 1933, as amended (the
Securities Act), covering $ in aggregate principal amount of shares of the Companys common stock, $0.001 par value per share (the Common Stock), to be issued and sold from time to
time pursuant to Rule 415 under the Securities Act. This opinion letter is being rendered pursuant to Item 16 of Form S-3 and Item 601(b)(5) of Regulation S-K.
We have examined the Amended and Restated Certificate of Incorporation of the Company, the Restated Bylaws of the Company, records of
proceedings of the Board of Directors, or committees thereof, and records of proceedings of the stockholders, deemed by us to be relevant to this opinion letter and the Registration Statement. We also have made such further legal and factual
examinations and investigations as we deemed necessary for purposes of expressing the opinion set forth herein.
As to certain factual
matters relevant to this opinion letter, we have relied conclusively upon originals or copies, certified or otherwise identified to our satisfaction, of such records, agreements, documents and instruments, including certificates or comparable
documents of officers of the Company and of public officials, as we have deemed appropriate as a basis for the opinion hereinafter set forth. Except to the extent expressly set forth herein, we have made no independent investigations with regard to
matters of fact, and, accordingly, we do not express any opinion as to matters that might have been disclosed by independent verification. We assume no obligation to revise or supplement this opinion in the event of future changes in such facts.
Atlanta Brussels Charlotte Dallas Los Angeles New York Research
Triangle Silicon Valley Ventura County Washington, D.C.
January 20, 2015
Page
2
Based on the foregoing and subject to the limitations, qualifications, exceptions and
assumptions set forth herein, we are of the opinion that the Common Stock will be validly issued, fully paid and non-assessable. This opinion is conditioned upon the Board of Directors of the Company or a duly authorized committee thereof (the
Board of Directors) having validly authorized and approved the filing of the Registration Statement, so as not to violate any applicable law, rule or regulation or result in a default under or a breach of any agreement binding
upon the Company and so as to comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company. Furthermore, this opinion is contingent upon the proper execution, authentication, issuance and
delivery of such Common Stock, as the case may be, as contemplated by the Registration Statement and any prospectus supplement relating thereto, and in accordance with any underwriting agreement in exchange for the consideration fixed therefor by
the Board of Directors or a duly authorized committee thereof (provided that the consideration paid is not less than the par value thereof).
The opinion set forth herein is limited to the General Corporation Law and Constitution of the State of Delaware and reported judicial
decisions interpreting the foregoing, and federal laws of the United States of America to the extent referred to specifically herein. We do not express any opinion herein concerning any other laws. We are not engaged in the practice in the State of
Delaware; however, we are generally familiar with the Delaware General Corporation Law as currently in effect and have made such inquiries as we consider necessary to render the opinion contained herein. We assume no obligation to revise or
supplement this opinion in the event of future changes in such laws or the interpretations thereof.
The opinion set forth above is
subject to (i) the effect of any bankruptcy, insolvency, reorganization, moratorium, arrangement or similar laws affecting the rights and remedies of creditors generally, including the effect of statutory or other laws regarding fraudulent or
preferential transfers, and (ii) general principles of equity, including concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance, injunctive relief or other equitable remedies
regardless of whether enforceability is considered in a proceeding in equity or at law. We express no opinion regarding the effectiveness of (i) any waiver of stay, extension or usury laws or of unknown future rights; or (ii) provisions
may be held unenforceable as contrary to federal or state securities laws.
No opinion may be implied or inferred beyond the opinion
expressly stated in the paragraph above. Our opinion expressed herein is as of the date hereof, and we undertake no obligation to advise you of any changes in applicable law or any other matters that may come to our attention after the date hereof
that may affect our opinion expressed herein.
We consent to the filing of this opinion letter as an exhibit to the Registration Statement
and to the use of our name under the heading Legal Matters in the
January 20, 2015
Page
3
prospectus constituting a part thereof. In giving such consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities
Act or the rules and regulations of the Commission thereunder.
|
|
|
Very truly yours, |
|
ALSTON & BIRD LLP |
|
|
By: |
|
/s/ Mark F. McElreath |
|
|
Mark F. McElreath |
|
|
Partner |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in this Registration Statement on Form S-3 filed on January 20, 2015 of our reports dated March 12, 2014,
with respect to the consolidated balance sheets of Keryx Biopharmaceuticals, Inc. and Subsidiaries, as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive loss, stockholders equity, and cash
flows for each of the years in the three-year period ended December 31, 2013, which report expresses an unqualified opinion, appearing in the Annual Report on Form 10-K of Keryx Biopharmaceuticals, Inc. for the three years ended
December 31, 2013, and the effectiveness of internal control over financial reporting as of December 31, 2013. We also hereby consent to the reference to our firm under the heading Experts in this registration statement.
/s/ UHY LLP
New York, New York
January 20, 2015
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2023 to Mar 2024